

Gavin Robert M.
Form 4
October 30, 2017

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
Gavin Robert M.

(Last) (First) (Middle)

C/O BIO-TECHNE
CORPORATION, 614 MCKINLEY
PLACE NE

(Street)

MINNEAPOLIS, MN 55413

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading
Symbol
BIO-TECHNE Corp [TECH]

3. Date of Earliest Transaction
(Month/Day/Year)
10/26/2017

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

____ Director ____ 10% Owner
____ Officer (give title ____ Other (specify
below) below)
Sen. VP Protein Platforms

6. Individual or Joint/Group Filing(Check
Applicable Line)
X Form filed by One Reporting Person
____ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
				(A) or (D)			
				Code V Amount (D) Price			
Common Stock					1,667	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of
information contained in this form are not
required to respond unless the form
displays a currently valid OMB control
number.**

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Gavin Robert M. - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	10/26/2017		A		1,949		(2)	(2)	Common Stock	1,949
Stock Options (Right to buy)	\$ 125.05	10/26/2017		A		10,742		(2)	08/09/2024	Common Stock	10,742
Stock Options (Right to buy)	\$ 125.05	10/26/2017		A		14,323		(3)	08/09/2024	Common Stock	14,323
Restricted Stock Units	(4)							(5)	(5)	Common Stock	1,500
Restricted Stock Units	(1)							(6)	(6)	Common Stock	2,111
Stock Option (Right to Buy)	\$ 108.49							(7)	08/07/2022	Common Stock	12,500
Stock Option (Right to Buy)	\$ 108.49							(5)	08/07/2022	Common Stock	9,375
Stock Option (Right to Buy)	\$ 93.32							(8)	07/31/2021	Common Stock	10,000
Stock Option (Right to Buy)	\$ 90.25							(9)	11/30/2021	Common Stock	5,000
Stock Options	\$ 106.59							(6)	08/18/2023	Common Stock	13,028

(Right to
buy)

Stock

Options
(Right to
buy)

\$ 106.59

(10)

08/18/2023

Common
Stock

17,371

Stock

Options
(Right to
buy)

\$ 93.32

(11)

07/31/2021

Common
Stock

16,667

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Gavin Robert M. C/O BIO-TECHNE CORPORATION 614 MCKINLEY PLACE NE MINNEAPOLIS, MN 55413			Sen. VP Protein Platforms	

Signatures

/s/ Brenda S. Furlow, attorney in fact for Robert M. Gavin pursuant to Power of Attorney
filed here with

10/30/2017

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- (2) Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- (3) Vests 3,580 shares on 8/9/2018 and 3,581 shares each on 8/9/2019, 8/9/2020, 8/9/2021.
- (4) Each restricted stock unit represents a contingent right to receive one shares of Bio-Techne common stock.
- (5) Vests in full or in part on 8/7/18 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- (6) Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- (7) 3,125 shares vest on each of 8/7/16, 8/7/17, 8/7/18 and 8/7/19.
- (8) 2,500 shares vest on each of 7/31/15, 7/31/16, 7/31/17 and 7/31/18.
- (9) 1,500 shares vest on each of 12/1/15, 12/1/16, 12/1/17 and 12/1/18.
- (10) Vests 4,343 shares on each 8/18/2017, 8/18/2018 and 8/18/2019 and 4,342 shares on 8/18/2020
- (11) Fully exercisable

Remarks:

Edgar Filing: Gavin Robert M. - Form 4

Due to an administrative error, the Form 4 filed by Reporting Person on February 3, 2017 contained a duplicate of the Table II

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.